Free Trial
→ My top 3 AI picks for the next decade (From The Oxford Club) (Ad)tc pixel
OTCMKTS:FSNUY

Fresenius SE & Co. 11/6/2024 Earnings Results & Report

Fresenius SE & Co. logo
$12.08 -0.11 (-0.90%)
As of 03:58 PM Eastern

Fresenius SE & Co. reported earnings on November 6, 2024. The company reported EPS of $0.19, while revenue was $5.90 billion.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Report Date
Time
Before Market Opens

Fresenius SE & Co. EPS Results

Actual EPS
$0.19
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 5 quarters

Fresenius SE & Co. Revenue Results

Actual Revenue
$5.90 billion
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Fresenius SE & Co.'s next earnings date is estimated for Wednesday, November 4, 2026, based on past reporting schedules.

Conference Call Resources

Fresenius SE & Co. Earnings FAQ

Fresenius SE & Co. (OTCMKTS:FSNUY) reported earnings of $0.19 per share for the quarter. The report was announced on Wednesday, November 6, 2024.

Fresenius SE & Co. reported revenue of $5.90 billion for the quarter.

Fresenius SE & Co.'s next earnings date is estimated for Wednesday, November 4, 2026. MarketBeat tracks confirmed and estimated earnings dates for Fresenius SE & Co. on the company's earnings history page.

Fresenius SE & Co. Earnings Headlines

Fresenius : Q3 2026 Aide Memoire available
October 13 at 1:13 PM  |  marketscreener.comM
Fresenius SE & Co. (OTCMKTS:FSNUY) Shares Gap Up - Time to Buy?
October 12 at 11:01 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31111113
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
October 13 at 1:00 AM  |  Profits Run (Ad)
Fresenius Acquires Remaining 45% Stake In MAbxience For Up To EUR 750 Mln
October 1, 2026  |  rttnews.comhttps://www.rttnews.com/3695605/fresenius-acquires-remaining-45-stake-in-mabxience-for-up-to-eur-750-mln.aspx
Fresenius SE Takes Full Ownership of Biosimilars Platform mAbxience
October 1, 2026  |  marketscreener.comM
Waltz Health and Fresenius Kabi Expand Direct Access to Biosimilars Through Waltz Connect Platform
September 29, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/waltz-health-and-fresenius-kabi-expand-direct-access-to-biosimilars-through-waltz-connect-platform-302892345.html
See More Fresenius SE & Co. Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Fresenius SE & Co.? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fresenius SE & Co. and other key companies, straight to your email.

About Fresenius SE & Co.

Fresenius SE & Co. (OTCMKTS:FSNUY) KGaA is a German healthcare company headquartered in Bad Homburg, Germany. The group develops and provides products and services for hospitals, outpatient care providers and patients, with operations focused primarily on healthcare products and hospital services.

Its Fresenius Kabi business supplies medicines and technologies used in infusion therapy, clinical nutrition and transfusion medicine. Its portfolio includes intravenous drugs, generic medicines, biosimilars, infusion systems, medical devices and products for parenteral and enteral nutrition.

Fresenius also operates hospitals through Helios, which manages acute-care and rehabilitation facilities in Germany and hospitals and other healthcare services in Spain through the Quirónsalud network. The company traces its origins to a pharmacy established by Dr. Eduard Fresenius in Frankfurt in 1912. Michael Sen has served as chief executive officer since 2022.

View Fresenius SE & Co. Profile
Earnings Tools